Welcome to our dedicated page for United Therapeutics SEC filings (Ticker: UTHR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Pulmonary arterial hypertension isn’t the only complex topic inside United Therapeutics’ disclosures. Investors hunting for revenue splits on treprostinil therapies, updates on organ manufacturing, or milestones in rare-disease trials often scroll through hundreds of pages. Our page delivers United Therapeutics SEC filings explained simply, turning every dense 10-K footnote or 8-K headline into plain-language insights. So when you search for “United Therapeutics 8-K material events explained,” you arrive at answers, not endless PDFs.
Stock Titan’s AI reads each United Therapeutics quarterly earnings report 10-Q filing the instant it posts to EDGAR, extracts cash-flow shifts, R&D spend, and segment growth, then produces a concise United Therapeutics earnings report filing analysis. The same engine delivers a United Therapeutics annual report 10-K simplified, flags evolving risk factors, and stitches multi-year trends—ideal for understanding United Therapeutics SEC documents with AI. Real-time alerts trigger the moment United Therapeutics Form 4 insider transactions real-time appear, ensuring you never miss executive moves.
Need deeper governance context? Track United Therapeutics insider trading Form 4 transactions or review United Therapeutics executive stock transactions Form 4 alongside the latest United Therapeutics proxy statement executive compensation. Whether you’re monitoring clinical trial spend, covenant triggers, or valuation drivers, every filing type—10-K, 10-Q, 8-K, S-8—arrives within seconds and is paired with expert commentary. Stop digging; let AI surface what matters most.
Paul A. Mahon, EVP & General Counsel of United Therapeutics Corporation (UTHR), reported option exercises and related stock sales on 08/21/2025 under a pre-arranged 10b5-1 plan entered on December 24, 2024. He exercised 11,000 stock options with an exercise price of $135.42 (options dated 03/15/2023, expiring 03/15/2027) and sold the resulting shares in multiple trades at weighted-average prices ranging from about $305.63 to $310.51 (individual weighted averages reported). The filings show the sales disposed of all 11,000 exercised shares, reducing reported beneficial ownership from 47,781 to 36,781 shares while leaving 77,000 options outstanding. Transactions were executed pursuant to the 10b5-1 plan; the reporting person offered to provide trade-level details on request.
Form 144 notice for proposed sale of securities under Rule 144. The filing shows 11,000 shares of common stock to be sold through Morgan Stanley Smith Barney LLC on 08/21/2025 with an aggregate market value of $3,396,248.90 and the issuer reported 45,226,262 shares outstanding. The securities were acquired on 08/21/2025 by stock option exercise and payment was in cash. The filing also lists multiple recent sales by Paul Mahon totaling 66,000 shares in the past three months. The notice includes the standard signature representation that the seller has no undisclosed material adverse information.
Paul A. Mahon, EVP & General Counsel of United Therapeutics (UTHR), exercised 11,000 stock options at an exercise price of $135.42 on 08/07/2025 and sold the resulting 11,000 shares pursuant to a pre-arranged 10b5-1 plan entered December 24, 2024. The sales were executed in multiple tranches with reported weighted-average prices ranging from $297.4924 to $303.45, and explanatory notes list the trade-price ranges for each tranche. After these transactions Mahon beneficially owned 36,781 common shares and continued to hold 88,000 exercisable stock options. The Form 4 reports the option exercise, the subsequent share disposals, and post-transaction holdings.
United Therapeutics Corp. (UTHR) has filed a Form S-8 to register 950,000 additional common shares (par $0.01) for issuance under its Amended & Restated 2015 Stock Incentive Plan. The company relies on General Instruction E, incorporating eight prior S-8 filings that together registered 13,820,000 shares; cumulative authorization for the plan now totals 14,770,000 shares. UTHR is incorporated in Delaware, qualifies as a large accelerated filer, and lists its principal executive offices in Silver Spring, MD.
The filing, signed by Chair & CEO Martine A. Rothblatt on 30 July 2025, contains standard exhibits such as the counsel opinion, auditor consent, and plan document. No financial statements, earnings data, or new corporate events are included; the registration strictly facilitates future equity compensation grants.
United Therapeutics (UTHR) Form 4: EVP & General Counsel Paul A. Mahon exercised 11,000 stock options at an exercise price of $135.42 on 07/24/2025, converting them into common shares. The same day, he disposed of the entire 11,000-share lot through three open-market sales executed under a pre-arranged Rule 10b5-1 plan at weighted-average prices of $303.31, $304.25 and $305.14, generating gross proceeds of roughly $3.3 million and a spread of about $168 per share over the strike price.
Following the transactions Mahon retains 36,781 shares of common stock held directly and continues to hold 99,000 unexercised options (same grant, expiring 03/15/2027). No other classes of securities were affected.
The filing represents routine insider activity disclosed within two business days and does not alter company guidance or fundamentals. Investors often monitor insider sales for sentiment signals; however, the use of a 10b5-1 plan and the retention of a sizable equity stake temper any negative inference.
FAQ
What is the current stock price of United Therapeutics (UTHR)?
What is the market cap of United Therapeutics (UTHR)?
